ConductScience.org, home

Paper38337010

Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction.

Muluhie M and 5 others. Sci Rep, 2024. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction. Papers, record 38337010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38337010

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Montelukast, an available and safe anti-asthmatic drug, prevents maladaptive remodelling and maintains cardiac functionality following myocardial infarction.
PubMed
Journal
Sci Rep
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
1.45, provisional
iCite
Revised in PubMed
2024-02-14
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Muluhie MMajeda
2Castiglioni LLaura
3Rzemieniec JJoanna
4Mercuriali BBenedetta
5Gelosa PPaolo
6Sironi LLuigi

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ventricular RemodelingMajor topic
Myocardial InfarctionMajor topic
AcetatesMajor topic
CyclopropanesMajor topic
QuinolinesMajor topic
SulfidesMajor topic
Mice
Animals
Female
Mice, Inbred C57BL
Myocardium

Source PubMed

Download CSV of topics

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130310233Drug repurposing: progress, challenges and recommendations.Nat Rev Drug Discov2019https://conductscience.org/library/papers/30310233PubMed
230513339The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions.Drug Discov Today2019https://conductscience.org/library/papers/30513339PubMed
318949546Leukotriene signaling in atherosclerosis and ischemia.Cardiovasc Drugs Ther2009https://conductscience.org/library/papers/18949546PubMed
420093252The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease.Cardiovasc Res2010https://conductscience.org/library/papers/20093252PubMed
522434418Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.Med Res Rev2013https://conductscience.org/library/papers/22434418PubMed
628246014Montelukast inhibits oxidized low-density lipoproteins (ox-LDL) induced vascular endothelial attachment: An implication for the treatment of atherosclerosis.Biochem Biophys Res Commun2017https://conductscience.org/library/papers/28246014PubMed
718953103The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice.J Physiol Pharmacol2008https://conductscience.org/library/papers/18953103PubMed
819110249Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.Atherosclerosis2009https://conductscience.org/library/papers/19110249PubMed
919998057Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits.Cardiovasc Drugs Ther2009https://conductscience.org/library/papers/19998057PubMed
1029432192Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm.Proc Natl Acad Sci U S A2018https://conductscience.org/library/papers/29432192PubMed
1122527886Cysteinyl leukotriene signaling through perinuclear CysLT(1) receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression.J Mol Med (Berl)2012https://conductscience.org/library/papers/22527886PubMed
1231313075Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.Inflammopharmacology2019https://conductscience.org/library/papers/31313075PubMed
1316990797The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.EMBO J2006https://conductscience.org/library/papers/16990797PubMed
1430818044Improvement of fiber connectivity and functional recovery after stroke by montelukast, an available and safe anti-asthmatic drug.Pharmacol Res2019https://conductscience.org/library/papers/30818044PubMed
1522244598Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease.J Allergy Clin Immunol2012https://conductscience.org/library/papers/22244598PubMed
1633519477Montelukast Use Decreases Cardiovascular Events in Asthmatics.Front Pharmacol2020https://conductscience.org/library/papers/33519477PubMed
1717646220The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics.Chest2007https://conductscience.org/library/papers/17646220PubMed
1821112334Inhibition of leukotriene C4 action reduces oxidative stress and apoptosis in cardiomyocytes and impedes remodeling after myocardial injury.J Mol Cell Cardiol2011https://conductscience.org/library/papers/21112334PubMed
1926089034Montelukast attenuates lipopolysaccharide-induced cardiac injury in rats.Hum Exp Toxicol2016https://conductscience.org/library/papers/26089034PubMed
2035358494Montelukast, cysteinyl leukotriene receptor 1 antagonist, inhibits cardiac fibrosis by activating APJ.Eur J Pharmacol2022https://conductscience.org/library/papers/35358494PubMed

See all 52 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42401692Molecular mechanisms of coronary microembolization-induced MINOCA.Basic Res Cardiol2026https://conductscience.org/library/papers/42401692PubMed
41870545Montelukast impressively mitigates biomarkers of inflammation in non-ST-segment elevation myocardial infarction patients: a randomized, double-blind, placebo-controlled clinical trial.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41870545PubMed
40715741New insights on pharmacological potential of montelukast: a comprehensive review.Inflammopharmacology2025https://conductscience.org/library/papers/40715741PubMed
40512240Molecular screening in a translational large animal trial identifies a differential inflammatory response for MINOCA.Basic Res Cardiol2025https://conductscience.org/library/papers/40512240PubMed
40234645Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation.Sci Rep2025https://conductscience.org/library/papers/40234645PubMed
39327397Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences.Drugs2024https://conductscience.org/library/papers/39327397PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38337010

GET https://conductscience.org/api/papers/v1/38337010/references?page=2